𝘛𝘰𝘱𝘤𝘰𝘯 𝘔𝘢𝘬𝘪𝘯𝘨 𝘔𝘰𝘷𝘦𝘴: 𝘈𝘤𝘲𝘶𝘪𝘴𝘪𝘵𝘪𝘰𝘯𝘴 𝘢𝘯𝘥 𝘐𝘯𝘷𝘦𝘴𝘵𝘮𝘦𝘯𝘵𝘴

1️⃣ Acquisition of Toku, Inc.
Topcon has signed a definitive agreement to acquire Toku, a San Diego–based AI health tech company whose platforms — CLAiR, BioAge Labs, and MyKidneyAI — use retinal imaging to assess cardiovascular risk, biological ageing, and chronic kidney disease.
✨ This acquisition strengthens Topcon’s mission to make non-invasive, AI-driven risk screening more accessible across both primary care and eyecare.
By combining Topcon’s global reach with Toku’s advanced AI, this partnership will help improve population health outcomes, reduce healthcare costs, and detect serious disease risks years earlier than traditional methods.
2️⃣ Strategic Investment in Sanro Health, Inc.
Topcon has also made a strategic investment in Sanro Health, a clinician-founded company dedicated to connecting and interpreting ophthalmic data and medical images.
Sanro’s platform transforms fragmented data into actionable insights — enabling intelligent patient profiles and real-time clinical trial matching.
🩺 This collaboration empowers clinicians to gain a complete view of each patient’s medical history, supporting faster, more informed decisions — and bridging the gap between patient care and research.
Together, these moves reflect Topcon’s commitment to advancing AI-powered healthcare, bringing together technology, data, and patient outcomes to build a smarter, more connected future for medicine.